Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

Phase 4

Completed

Conditions: Chronic Myelogenous Leukemia in Chronic Phase
Philadelphia Chromosome Positive

Interventions: Drug: Nilotinib

First Posted Date: 2010-01-07

Last Posted Date: 2016-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT01043874

Locations: 🇯🇵
Novartis Investigative Site, Saga, Japan

Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Phase 3

Terminated

Conditions: Leukaemia, Lymphocytic, Chronic

Interventions: Biological: Ofatumumab
Other: Observation

First Posted Date: 2009-12-25

Last Posted Date: 2019-07-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 480

Registration Number: NCT01039376

Locations: 🇺🇦
Novartis Investigative Site, Zhytomyr, Ukraine

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Phase 3

Terminated

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Drug: LCZ696 200 mg BID
Drug: Enalapril 10 mg BID

First Posted Date: 2009-12-18

Last Posted Date: 2016-08-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8442

Registration Number: NCT01035255

Locations: 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela

Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Phase 3

Completed

Conditions: Carcinoma

Interventions: Drug: Everolimus Placebo
Drug: Everolimus
Other: Best Supportive Care (BSC)

First Posted Date: 2009-12-18

Last Posted Date: 2016-09-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 546

Registration Number: NCT01035229

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
🇺🇸
University of California San Diego - Moores Cancer Center SC - 3, La Jolla, California, United States
🇺🇸
Compassionate Cancer Care Medical Group CCCMG, Fountain Valley, California, United States

and more 17 locations

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)

Phase 3

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Panobinostat
Drug: Placebo

First Posted Date: 2009-12-17

Last Posted Date: 2016-07-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT01034163

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore
🇺🇸
Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
🇺🇸
Northwestern University Oncology, Chicago, Illinois, United States

and more 11 locations

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: LBH589
Drug: Epoetin Alfa

First Posted Date: 2009-12-17

Last Posted Date: 2017-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT01034657

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Safety and Efficacy of DNK333 in Atopic Dermatitis Patients

Phase 2

Completed

Conditions: Pruritus in Patients With Atopic Dermatitis

Interventions: Drug: DNK333 5 mg
Drug: Placebo to 5 mg
Drug: DNK333 25 mg
Drug: Placebo to 25 mg
Drug: DNK333 100 mg
Drug: Placebo to 100 mg
Drug: Betamethasone 4 mg
Drug: DNK333 1mg
Drug: Placebo to 1mg

First Posted Date: 2009-12-16

Last Posted Date: 2017-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT01033097

Locations: 🇩🇪
Novartis Investigative Site, Munster, Germany
🇩🇪
Novartis Investigator Site, Hannover, Germany

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Phase 3

Terminated

Conditions: Non-infectious Uveitis

Interventions: Biological: AIN457
Drug: Placebo

First Posted Date: 2009-12-16

Last Posted Date: 2015-11-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 125

Registration Number: NCT01032915

Locations: 🇺🇸
OHSU, Casey Eye Institute, Portland, Oregon, United States
🇺🇸
Houston Eye Associates, Houston, Texas, United States
🇺🇸
Charlotte Eye, Ear, Nose, and Throat Associates, Belmont, North Carolina, United States

and more 11 locations

To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Phase 2

Terminated

Conditions: Sporadic Superficial and Nodular Skin Basal Cell Carcinomas

Interventions: Drug: LDE225 0.75%
Drug: Vehicle

First Posted Date: 2009-12-16

Last Posted Date: 2015-10-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT01033019

Locations: 🇦🇹
Novartis Investigative Site, Wien, Austria

Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study

Phase 2

Completed

Conditions: Liver Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2009-12-16

Last Posted Date: 2011-08-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 70

Registration Number: NCT01033747

Locations: 🇮🇹
Novartis Investigative Site, Torino, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy